<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04587011</url>
  </required_header>
  <id_info>
    <org_study_id>IN_APA_119</org_study_id>
    <nct_id>NCT04587011</nct_id>
  </id_info>
  <brief_title>A Study to Explore Pharmacokinetics/Pharmacodynamics and Safety of Tegoprazan BID Dosing in Healthy Subjects</brief_title>
  <official_title>A Phase 1 Clinical Trial to Explore Pharmacokinetics, Pharmacodynamics and Safety After Twice-daily Dosing of Tegoprazan Tablets in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to explore the pharmacokinetics, pharmacodynamics and&#xD;
      safety after twice-daily dosing of tegoprazan tablets in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To explore the pharmacokinetics, pharmacodynamics and safety in accordance with the dose&#xD;
           escalation when tegoprazan is given orally twice daily for 3 days in healthy subjects.&#xD;
&#xD;
        -  To compare the pharmacodynamics and safety of tegoprazan oral administration and&#xD;
           esomeprazole infusion for 24 hours&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Cmax of Tegoprazan and M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>AUC0-t of Tegoprazan and M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>AUC0-∞ of Tegoprazan and M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Tmax of Tegoprazan and M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>t1/2β of Tegoprazan and M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>CL/F of Tegoprazan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Vd/F of Tegoprazan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Css,max of Tegoprazan and M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Css,min of Tegoprazan and M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Css,avg of Tegoprazan and M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>AUC48-72h of Tegoprazan and M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Tmax,ss of Tegoprazan and M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>t1/2β,ss of Tegoprazan and M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>CLss/F of Tegoprazan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Vdss/F of Tegoprazan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Evaluation</measure>
    <time_frame>24 hours</time_frame>
    <description>Mean pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Evaluation</measure>
    <time_frame>24 hours</time_frame>
    <description>Median pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Evaluation</measure>
    <time_frame>24 hours</time_frame>
    <description>TpH&gt;4(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Evaluation</measure>
    <time_frame>24 hours</time_frame>
    <description>TpH&gt;6(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Evaluation</measure>
    <time_frame>24 hours</time_frame>
    <description>Basal pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Evaluation</measure>
    <time_frame>24 hours</time_frame>
    <description>Δ TpH&gt;4(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Evaluation</measure>
    <time_frame>24 hours</time_frame>
    <description>Δ TpH&gt;6(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Evaluation</measure>
    <time_frame>24 hours</time_frame>
    <description>Δ mean pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Evaluation</measure>
    <time_frame>24 hours</time_frame>
    <description>Δ median pH</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan A mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan B mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan C mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan D mg or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan dose A or placebo</intervention_name>
    <description>Tegoprazan A mg or placebo taken orally twice daily for 3 days.</description>
    <arm_group_label>T1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan dose B or placebo</intervention_name>
    <description>Tegoprazan B mg or placebo taken orally twice daily for 3 days.</description>
    <arm_group_label>T2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan dose C or placebo</intervention_name>
    <description>Tegoprazan C mg or placebo taken orally twice daily for 3 days.</description>
    <arm_group_label>T3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan dose D or placebo</intervention_name>
    <description>Tegoprazan D mg or placebo taken orally twice daily for 3 days.</description>
    <arm_group_label>T4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects aged 19 to 45(inclusive) years at screening.&#xD;
&#xD;
          -  Subjects with body mass index (BMI) in the range of 18.5 kg/m^2 to 28.0&#xD;
             kg/m^2(inclusive)&#xD;
&#xD;
          -  Subjects who voluntarily agreed to participate in the study after being fully informed&#xD;
             of the purpose, content, and characteristics of the investigational product(IP) prior&#xD;
             to the study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Past medical history&#xD;
&#xD;
               -  Subjects who are determined by the investigator to have clinically significant&#xD;
                  history or disease related to the liver, kidney, digestive system, respiratory&#xD;
                  system, musculoskeletal system, endocrine system, neuropsychiatric system,&#xD;
                  hemato-oncology system, urinary system and cardiovascular system including&#xD;
                  cardiac arrhythmia.&#xD;
&#xD;
               -  Subjects who are determined by the investigator to have past history of&#xD;
                  gastrointestinal diseases (ex.: gastritis, GERD, Crohn's disease, ulcers etc.) or&#xD;
                  abdominal surgery (except simple appendectomy or herniotomy) that may affect the&#xD;
                  IP absorption.&#xD;
&#xD;
          2. Diagnostic test and electrocardiogram (ECG)&#xD;
&#xD;
               -  If H. pylori test result is positive at screening&#xD;
&#xD;
               -  If the AST or ALT value is more than 1.25 times the upper limit of normal under&#xD;
                  the screening test&#xD;
&#xD;
               -  If the total bilirubin value is more than 1.5 times the upper limit of normal&#xD;
                  under the screening test&#xD;
&#xD;
               -  If the eGFR calculated by CKD-EPI formula is less than 80 mL/min at screening&#xD;
&#xD;
               -  Subjects showing clinically significant abnormalities on ECG at screening&#xD;
&#xD;
          3. Allergy and drug abuse&#xD;
&#xD;
               -  Subjects who are hypersensitive to the investigational product or its active&#xD;
                  ingredient and any other medications (aspirin, antibiotics etc.)&#xD;
&#xD;
               -  Subjects with history of substance abuse or positive results from drug screening&#xD;
                  test.&#xD;
&#xD;
          4. Contraindicated drugs/foods&#xD;
&#xD;
               -  Subjects who have been taking any medications (including herbal medicines) or on&#xD;
                  an abnormal diet (ex: consuming more than 1L of grapefruit juice per day, large&#xD;
                  amounts of garlic, broccoli and kale, etc.) that can affect the absorption,&#xD;
                  distribution, metabolism and excretion of the IP within 28 days from the first IP&#xD;
                  administration date&#xD;
&#xD;
               -  Subjects who took any prescription drugs(ETC) or any over-the-counter drugs(OTC)&#xD;
                  within 10 days from the first IP administration date&#xD;
&#xD;
               -  Subjects who participated in other clinical trials or bioequivalence test and&#xD;
                  received other investigational product within 6 months from the first day of the&#xD;
                  IP administration (allowed to participate only if the other investigational&#xD;
                  product(s) was(were) not taken)&#xD;
&#xD;
          5. Blood donation and transfusion&#xD;
&#xD;
               -  Subjects who donated whole blood within 60 days from the first day of the&#xD;
                  investigational product administration&#xD;
&#xD;
               -  Subjects who received blood transfusion or made apheresis blood donation within&#xD;
                  30 days from the first day of the IP administration&#xD;
&#xD;
          6. Pregnancy, Breastfeeding, and Contraception&#xD;
&#xD;
               -  Women who are pregnant, breast-feeding or have positive result on pregnancy test.&#xD;
&#xD;
               -  Subjects who are unable to use medically proven dual contraceptive methods or&#xD;
                  medically acceptable contraceptive method (intrauterine device with proven&#xD;
                  pregnancy failure rate, concurrent use of physical barrier method and spermicide,&#xD;
                  vasectomy, tubectomy/ligation, and hysterectomy, etc.) by the subject or spouse&#xD;
                  or partner from the screening date to 30 days after the last IP administration&#xD;
                  date.&#xD;
&#xD;
          7. Others&#xD;
&#xD;
               -  Subjects whose weekly alcohol intake exceeds 30g/day in the last 4 weeks prior to&#xD;
                  the screening visit or found positive on alcohol test&#xD;
&#xD;
               -  Subjects who smoke more than 10 cigarettes/day per week over the last 4 weeks&#xD;
                  prior to the screening visit&#xD;
&#xD;
               -  Subjects with caffeine consumption of more than 400mg/day per week over the last&#xD;
                  4 weeks prior to the screening visit&#xD;
&#xD;
               -  Subjects with clinically significant findings that the investigator determined to&#xD;
                  be unqualified for participation in the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Lyul Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youngshin Keum, R.Ph, Pharm.D</last_name>
    <phone>+82-2-6477-0204</phone>
    <email>ys.keum@inno-n.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seokuee Kim, MD, PhD</last_name>
    <phone>+82-2-6477-0207</phone>
    <email>seokuee.kim@inno-n.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Lyul Kim, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

